Simona Soverini, Margherita Martelli, Luana Bavaro, Caterina De Benedittis, Cristina Papayannidis, Chiara Sartor, Federica Sorà, Francesco Albano, Sara Galimberti, Elisabetta Abruzzese, Mario Annunziata, Sabina Russo, Manuela Stulle, Annalisa Imovilli, Massimiliano Bonifacio, Elena Maino, Fabio Stagno, Claudia Maria Basilico, Erika Borlenghi, Claudio Fozza, Flavio Mignone, Roberta Minari, Stefania Stella, Michele Baccarani, Michele Cavo, Giovanni Martinelli
BCR-ABL1 kinase domain mutation testing in tyrosine kinase inhibitor (TKI)-resistant Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) patients is routinely performed by Sanger sequencing (SS). Recently, next-generation sequencing (NGS)-based approaches have been developed that afford greater sensitivity and straightforward discrimination between compound and polyclonal mutations. We performed a study to compare the results of SS and NGS in a consecutive cohort of 171 Ph+ ALL patients...
January 6, 2021: British Journal of Haematology